TL;DR: The Centers for Medicare & Medicaid Services modified NCD 19, the National Coverage Determination governing induced lesions of nerve tracts, effective January 9, 2026. Here's what billing teams need to know.
CMS nerve tract lesion coverage policy under NCD 19 in the Medicare system covers surgically induced nerve destruction procedures for chronic and acute pain management. This policy applies to denervation procedures including rhizolysis, chemical nerve destruction, and radio-frequency lesion creation (electrocautery). The policy does not list specific CPT or HCPCS codes — which creates real documentation and claim submission challenges your team needs to address now.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Induced Lesions of Nerve Tracts |
| Policy Code | NCD 19 |
| Change Type | Modified |
| Effective Date | January 9, 2026 |
| Impact Level | Medium |
| Specialties Affected | Pain Management, Neurosurgery, Interventional Radiology, Oncology, Orthopedic Surgery |
| Key Action | Audit your nerve ablation claims for medical necessity documentation and MAC concurrence before billing |
CMS Induced Nerve Tract Lesion Coverage Criteria and Medical Necessity Requirements 2026
NCD 19 is a National Coverage Determination that governs Medicare coverage of surgical and chemical nerve destruction procedures used to control chronic or acute pain. This coverage policy is narrower than many billing teams assume.
CMS covers these procedures when used in "selected cases" — and that phrase carries real weight. The policy requires concurrence from the Medicare Administrative Contractor's (MAC) medical staff for each case. That's not a checkbox. It means your MAC must affirmatively agree that the procedure is medically appropriate before you expect payment.
Medical necessity under NCD 19 is anchored to two primary conditions: terminal cancer and lumbar degenerative arthritis. The policy doesn't say these are the only covered indications, but it does use them as the defining examples. If your patient's condition falls outside those two, your documentation needs to work harder to establish medical necessity.
The three covered procedure types under this coverage policy are:
| # | Covered Indication |
|---|---|
| 1 | Rhizolysis — surgical cutting of the nerve |
| 2 | Chemical destruction — chemical ablation of nerve tissue |
| 3 | Radio-frequency lesion creation — electrocautery-based nerve destruction |
All three result in permanent or semi-permanent nerve ablation. CMS draws a hard line between these procedures and implanted neurostimulation devices. Nerve stimulation uses implanted electrodes to modulate pain signals. These nerve destruction procedures eliminate the nerve fibers entirely. NCD 19 covers ablation — not stimulation. If your team bills neurostimulation procedures, those fall under a completely separate coverage framework.
There is no mention of prior authorization requirements within NCD 19 itself. However, the MAC concurrence requirement functions similarly in practice. Build that verification step into your workflow before the procedure is performed, not after.
Coverage Indications at a Glance
| Indication | Coverage Status | Relevant Codes | Notes |
|---|---|---|---|
| Chronic pain from terminal cancer | Covered (when MAC concurs) | Not specified in NCD 19 | Strong medical necessity documentation required |
| Chronic pain from lumbar degenerative arthritis | Covered (when MAC concurs) | Not specified in NCD 19 | MAC medical staff concurrence required |
| Acute pain management (other conditions) | Covered in selected cases | Not specified in NCD 19 | Case-by-case MAC review; documentation-heavy |
| Neurostimulation / implanted electrode procedures | Not covered under NCD 19 | Separate NCD applies | Different policy governs; nerve fibers stimulated, not ablated |
CMS Nerve Tract Lesion Exclusions and Non-Covered Indications
NCD 19 does not cover implanted electrode procedures for pain control. That distinction is explicit in the policy text.
The real issue here is definitional. Stimulation-based pain procedures — spinal cord stimulators, dorsal root ganglion stimulation — are categorically excluded from NCD 19 coverage. They require electronic equipment post-operatively. NCD 19 procedures do not. If your physician is performing both types of procedures, make sure your charge capture separates them correctly.
The policy also doesn't extend coverage to all chronic pain conditions broadly. "Selected cases" is the operative phrase, and CMS has given your MAC the authority to define what that means regionally. That creates real variation across MAC jurisdictions. What gets approved in Jurisdiction J may not get approved in Jurisdiction L.
CMS Nerve Tract Lesion Billing Guidelines and Action Items 2026
The absence of specific CPT or HCPCS codes in this policy is your biggest practical challenge. Here's what to do before and after January 9, 2026.
| # | Action Item |
|---|---|
| 1 | Contact your MAC before billing any nerve ablation claim. The policy explicitly requires MAC medical staff concurrence in selected cases. Don't assume the procedure qualifies — get confirmation in writing. This is your front-line defense against claim denial. |
| 2 | Audit your charge capture for nerve destruction procedures immediately. Because NCD 19 lists no specific codes, your billing team must match the procedure to the correct CPT codes from the AMA code set independently. Rhizolysis, chemical neurolysis, and radio-frequency ablation each have distinct coding pathways. Make sure your coders know which pathway applies to each procedure type. |
| 3 | Separate nerve ablation claims from neurostimulation claims at the charge entry level. If your practice bills both categories, mislabeling a stimulation procedure as a destructive procedure — or vice versa — creates audit exposure. Build a charge entry crosswalk that flags these procedure types separately. |
| 4 | Document medical necessity with condition-specific detail. "Chronic pain" alone is not sufficient. Your documentation should name the underlying condition (terminal cancer, lumbar degenerative arthritis, or a comparable condition), describe why conservative management failed, and explain why nerve destruction is the appropriate next step. CMS reviewers and MAC medical staff will look for all three. |
| 5 | Check your MAC's local coverage policies for supplemental guidance. NCD 19 sets the national floor, but your MAC may have issued a Local Coverage Determination (LCD) that adds specificity — covered codes, documentation requirements, or prior auth steps. Search your MAC's website for LCDs related to nerve ablation, neurolysis, or rhizotomy before the effective date of January 9, 2026. |
| 6 | Train your clinical documentation team on the ablation vs. stimulation distinction. Operative reports and clinical notes should clearly state that the procedure destroyed nerve fibers rather than stimulating them, and that no implanted electronic equipment was placed. That language directly maps to NCD 19's coverage criteria and makes the claim easier to defend. |
| 7 | Review your reimbursement history for these procedures over the past 12 months. If you've had claim denial patterns on nerve destruction procedures, pull those cases now. Check whether MAC concurrence was documented. Check whether the underlying diagnosis supported medical necessity. Use this audit to fix your process before the January 9 effective date triggers heightened scrutiny. |
If your practice has significant volume of these procedures and you're uncertain how your MAC applies NCD 19 locally, talk to your compliance officer before the effective date. The MAC concurrence requirement creates enough ambiguity that a compliance review is worth the time.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Induced Nerve Tract Lesions Under NCD 19
No Specific Codes Listed in NCD 19
The Centers for Medicare & Medicaid Services does not list specific CPT, HCPCS Level II, or ICD-10-CM codes within NCD 19 itself. This is not an oversight — it reflects CMS's approach to this particular NCD, which focuses on clinical criteria and procedure type rather than specific code enumeration.
This puts the coding burden squarely on your billing team. You must identify the correct CPT codes for each nerve destruction procedure type using the AMA CPT code set, then map those codes to the coverage criteria in NCD 19. Your MAC's claims processing instructions and any applicable LCD are your best supplemental resources.
The procedure types described in NCD 19 — rhizolysis, chemical nerve destruction, and radio-frequency lesion creation — all have CPT coding pathways. Work with your coding team or a certified medical coder to identify the specific codes your physicians use. Then verify those codes against your MAC's LCD or billing guidelines.
The absence of listed codes in this policy is itself a billing risk. Claims for nerve ablation procedures without strong documentation linking the procedure to NCD 19's coverage criteria are vulnerable to denial on medical necessity grounds. Don't let the lack of a code table give you false confidence that anything goes.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.